Evinacumab

Among pediatric patients with homozygous familial hypercholesterolemia and elevated LDL despite optimal lipid-lowering therapy, evinacumab durably reduced LDL and other significant lipid parameters out to 72 weeks, a speaker reported.

The fully monoclonal angiopoietin-like 3 antibody evinacumab conferred sustained, long-term reductions in LDL and other atherogenic lipoproteins among patients with refractory hyperlipidemia, researchers reported.

Evinacumab-dgnb was estimated to increase life expectancy an additional 12 years among patients with homozygous familial hypercholesterolemia already on standard-of-care lipid-lowering therapies, researchers reported.

Regeneron Pharmaceuticals announced the FDA has extended approval of evinacumab-dgnb as an adjunct to other lipid-lowering therapy for the treatment of homozygous familial hypercholesterolemia in children aged 5 to 11 years.

Regeneron announced the FDA has accepted for priority review the supplemental biologics license application for evinacumab-dgnb as adjunctive treatment for homozygous familial hypercholesterolemia in children aged 5 to 11 years.

LDL reduction is the major focus in the primary and secondary prevention of atherosclerotic CVD.

In an update on FDA approvals and late-breaking trials in lipid therapies, a speaker reviewed the current and future landscapes of LDL- and triglyceride-lowering therapies.

Much research is being conducted on novel therapeutics to reduce residual lipid-related risks, a speaker said at the National Lipid Association Scientific Sessions.

In a phase 2 study, evinacumab reduced triglyceride levels in patients with severe hypertriglyceridemia but not familial chylomicronemia syndrome, a speaker reported at the American College of Cardiology Scientific Session.